ARTV

Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc. (ARTV) has 10 SEC Form 4 filings (14 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jul 14, 2026.

The most active filer is Director, 10% Owner RA CAPITAL MANAGEMENT, L.P. with 8 filings. Insiders have net bought $82.7M over the trailing 6 months. The largest single insider purchase in this window was $75.0M by Director, 10% Owner RA CAPITAL MANAGEMENT, L.P. on May 11, 2026.

  • Industry:Biotechnology
  • CEO:Fred Aslan
  • Employees:96
  • HQ:San Diego, CA, US
  • IPO:2024-07-19

Insider Buying

$83.1M

reported purchases (SEC code P)

Insider Selling

$478K

reported sales (SEC code S)

Unique Insiders

6

in the rolling window

Market Cap

$245.2M

latest known value

Source
Purchase$135KJul 14SEC ↗
Purchase$59KJul 14SEC ↗
Purchase$275KJun 29SEC ↗
Purchase$17KJun 29SEC ↗
Purchase$3.3MJun 11SEC ↗
Purchase$721Jun 11SEC ↗
Purchase$4.3MJun 11SEC ↗
Raymon HeatherFirst filing
Sale$28KMay 20SEC ↗
Horan ChristopherFirst filing
Sale$63KMay 20SEC ↗
Bush JenniferFirst filing
Sale$79KMay 20SEC ↗
Banerjee SubhashisFirst filing
Sale$63KMay 20SEC ↗
Aslan FredFirst filing
Sale$244KMay 20SEC ↗
Purchase$75.0MMay 13SEC ↗

Related companies

Artiva Biotherapeutics, Inc. is in the Healthcare sector.